[Combined therapy with recombinant alfa-2 and gamma interferons in patients with chronic hepatitis delta virus infection].
5 patients with chronic HD-viral infection received combined therapy with alpha 2 and gamma-interferons in daily doses 4000000 U for 30 days. In 1 patient with low-replicative form of hepatitis an AlAT activity decline and disappearance of serum IgM anti-D observed in the course of the treatment returned to pretreatment values one month after the end of therapy. In the other patient with high-replicative form of hepatitis a long suppression of viral replication was achieved, AlAT activity returned to normal. Low titers of IgM anti-D persisted for 5 months after therapy. The treatment failed in delta cirrhosis as activity of AlAT and IgM anti-D titers remained unchanged.
Fedorchenko
S V
SV
D000410:Alanine Transaminase / Q000097:blood; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D003699:Hepatitis D / Q000276:immunology / Q000628:therapy* / Q000821:virology; D003698:Hepatitis Delta Virus / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007370:Interferon Type I / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012074:Remission Induction; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects
D007075:Immunoglobulin M; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma; D000410:Alanine Transaminase
Kombinirovannaia terapiia rekombinantnym al'fa 2- i gamma-interferonom bol'nykh s khronicheskoĭ H del'ta-virusnoĭ infektsieĭ.